Definium Therapeutics, Inc.
DFTXHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Definium Therapeutics, Inc. (DFTX) is listed under Biotechnology. At a $5.14B market cap, Definium Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Market Cap
$5.14B
Beta
2.24
P/E (TTM)
—
P/E (Fwd)
-20.39
EPS (TTM)
$-3.43
EPS (Fwd)
$-1.88
ROE
-64.1%
ROA
-20.6%
Cash
$1.08B
Total Debt
$36.5M
Free CF
$7.6M
52W Change
289.9%
Annual Financials
Cash vs Debt
Where DFTX stands vs its 150-day and 200-day moving averages
As of the July 16, 2026 close, DFTX finished 111.49% above its 150-day moving average ($21.59) and 137.44% above its 200-day moving average ($19.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DFTX overbought or oversold?
At the July 16, 2026 close, DFTX's RSI(14) was 58.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Definium Therapeutics, Inc. holds $1.08B in cash against $36.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $7.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -64.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.24 means DFTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing DFTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.